메뉴 건너뛰기




Volumn 104, Issue 4, 2009, Pages 276-284

Abatacept, a Novel CD80/86-CD28 T Cell Co-stimulation Modulator, in the treatment of rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

EID: 62549154024     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00375.x     Document Type: Short Survey
Times cited : (98)

References (36)
  • 1
    • 34249720998 scopus 로고    scopus 로고
    • Cytokines in the pathogenesis of rheumatoid arthritis
    • McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007 7 : 429 42.
    • (2007) Nat Rev Immunol , vol.7 , pp. 429-42
    • McInnes, I.B.1    Schett, G.2
  • 3
    • 0036584028 scopus 로고    scopus 로고
    • Development of anti-TNF therapy for rheumatoid arthritis
    • Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002 2 : 364 71.
    • (2002) Nat Rev Immunol , vol.2 , pp. 364-71
    • Feldmann, M.1
  • 4
    • 28144441356 scopus 로고    scopus 로고
    • Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from north america and sweden: Association of susceptibility with PTPN22, CTLA4, and PADI4
    • Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from north america and sweden: Association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Human Genet 2005 77 : 1044 60.
    • (2005) Am J Human Genet , vol.77 , pp. 1044-60
    • Plenge, R.M.1    Padyukov, L.2    Remmers, E.F.3    Purcell, S.4    Lee, A.T.5    Karlson, E.W.6
  • 5
    • 33746940384 scopus 로고    scopus 로고
    • Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis
    • Klareskog L, Padyukov L, Lorentzen J, Alfredsson L. Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006 2 : 425 33.
    • (2006) Nat Clin Pract Rheumatol , vol.2 , pp. 425-33
    • Klareskog, L.1    Padyukov, L.2    Lorentzen, J.3    Alfredsson, L.4
  • 6
    • 33645700397 scopus 로고    scopus 로고
    • T-cell-targeted therapies in rheumatoid arthritis
    • Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol 2006 2 : 201 10.
    • (2006) Nat Clin Pract Rheumatol , vol.2 , pp. 201-10
    • Weyand, C.M.1    Goronzy, J.J.2
  • 7
    • 0032951538 scopus 로고    scopus 로고
    • Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent
    • Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999 90 : 65 78.
    • (1999) Clin Immunol , vol.90 , pp. 65-78
    • Klimiuk, P.A.1    Yang, H.2    Goronzy, J.J.3    Weyand, C.M.4
  • 8
    • 0032963292 scopus 로고    scopus 로고
    • CD28-deficient mice are highly resistant to collagen-induced arthritis
    • Tada Y, Nagasawa K, Ho A, Morito F, Ushiyama O, Suzuki N et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol 1999 162 : 203 8.
    • (1999) J Immunol , vol.162 , pp. 203-8
    • Tada, Y.1    Nagasawa, K.2    Ho, A.3    Morito, F.4    Ushiyama, O.5    Suzuki, N.6
  • 9
    • 0019955727 scopus 로고
    • An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies
    • Duke O, Panayi GS, Janossy G, Poulter LW. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982 49 : 22 30.
    • (1982) Clin Exp Immunol , vol.49 , pp. 22-30
    • Duke, O.1    Panayi, G.S.2    Janossy, G.3    Poulter, L.W.4
  • 11
    • 38349178776 scopus 로고    scopus 로고
    • Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice
    • Hsu H, Yang P, Wang J, Wu Q, Myers R, Chen J et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008 9 : 166 75.
    • (2008) Nat Immunol , vol.9 , pp. 166-75
    • Hsu, H.1    Yang, P.2    Wang, J.3    Wu, Q.4    Myers, R.5    Chen, J.6
  • 12
    • 0344585384 scopus 로고    scopus 로고
    • Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice
    • Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003 171 : 6173 7.
    • (2003) J Immunol , vol.171 , pp. 6173-7
    • Nakae, S.1    Nambu, A.2    Sudo, K.3    Iwakura, Y.4
  • 13
    • 0032939156 scopus 로고    scopus 로고
    • Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.
    • Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999 42 : 963 70.
    • (1999) Arthritis Rheum , vol.42 , pp. 963-70
    • Chabaud, M.1    Durand, J.M.2    Buchs, N.3    Fossiez, F.4    Page, G.5    Frappart, L.6
  • 14
    • 0023637951 scopus 로고
    • T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression
    • June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine- resistant interleukin 2 gene expression. Mol Cell Biol 1987 7 : 4472 81.
    • (1987) Mol Cell Biol , vol.7 , pp. 4472-81
    • June, C.H.1    Ledbetter, J.A.2    Gillespie, M.M.3    Lindsten, T.4    Thompson, C.B.5
  • 15
    • 0025963594 scopus 로고
    • Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
    • Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991 173 : 721 30.
    • (1991) J Exp Med , vol.173 , pp. 721-30
    • Linsley, P.S.1    Brady, W.2    Grosmaire, L.3    Aruffo, A.4    Damle, N.K.5    Ledbetter, J.A.6
  • 16
    • 16244389649 scopus 로고    scopus 로고
    • The B7/CD28 costimulatory family in autoimmunity
    • Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005 204 : 128 43.
    • (2005) Immunol Rev , vol.204 , pp. 128-43
    • Keir, M.E.1    Sharpe, A.H.2
  • 17
    • 33644967813 scopus 로고    scopus 로고
    • CTLA4Ig: Bridging the basic immunology with clinical application.
    • Bluestone JA, St. Clair E William, Turka LA. CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 2006 24 : 233 8.
    • (2006) Immunity , vol.24 , pp. 233-8
    • Bluestone, J.A.1    St. Clair, E.W.2    Turka, L.A.3
  • 19
    • 0027397169 scopus 로고
    • Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
    • Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993 177 : 165 73.
    • (1993) J Exp Med , vol.177 , pp. 165-73
    • Tan, P.1    Anasetti, C.2    Hansen, J.A.3    Melrose, J.4    Brunvand, M.5    Bradshaw, J.6
  • 20
    • 35948934705 scopus 로고    scopus 로고
    • Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity
    • Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007 34 : 2204 10.
    • (2007) J Rheumatol , vol.34 , pp. 2204-10
    • Davis, P.M.1    Abraham, R.2    Xu, L.3    Nadler, S.G.4    Suchard, S.J.5
  • 21
    • 0029162499 scopus 로고
    • Collagen-induced arthritis in the BB rat. prevention of disease by treatment with CTLA-4-ig
    • Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. prevention of disease by treatment with CTLA-4-ig. J Clin Invest 1995 96 : 987 93.
    • (1995) J Clin Invest , vol.96 , pp. 987-93
    • Knoerzer, D.B.1    Karr, R.W.2    Schwartz, B.D.3    Mengle-Gaw, L.J.4
  • 22
    • 0028153996 scopus 로고
    • B cell function in mice transgenic for mCTLA4-H gamma 1: Lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells
    • Lane P, Burdet C, Hubele S, Scheidegger D, Muller U, McConnell F et al. B cell function in mice transgenic for mCTLA4-H gamma 1: Lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells. J Exp Med 1994 179 : 819 30.
    • (1994) J Exp Med , vol.179 , pp. 819-30
    • Lane, P.1    Burdet, C.2    Hubele, S.3    Scheidegger, D.4    Muller, U.5    McConnell, F.6
  • 24
    • 0036275436 scopus 로고    scopus 로고
    • Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
    • Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002 46 : 1470 9.
    • (2002) Arthritis Rheum , vol.46 , pp. 1470-9
    • Moreland, L.W.1    Alten, R.2    Van Den Bosch, F.3    Appelboom, T.4    Leon, M.5    Emery, P.6
  • 25
    • 0242574700 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    • Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 349 : 1907 15.
    • (2003) N Engl J Med , vol.349 , pp. 1907-15
    • Kremer, J.M.1    Westhovens, R.2    Leon, M.3    Di Giorgio, E.4    Alten, R.5    Steinfeld, S.6
  • 26
    • 23644455857 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
    • Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 52 : 2263 71.
    • (2005) Arthritis Rheum , vol.52 , pp. 2263-71
    • Kremer, J.M.1    Dougados, M.2    Emery, P.3    Durez, P.4    Sibilia, J.5    Shergy, W.6
  • 27
    • 33645806121 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life
    • Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006 33 : 681 9.
    • (2006) J Rheumatol , vol.33 , pp. 681-9
    • Emery, P.1    Kosinski, M.2    Li, T.3    Martin, M.4    Williams, G.R.5    Becker, J.C.6
  • 28
    • 33745291091 scopus 로고    scopus 로고
    • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
    • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006 144 : 865 76.
    • (2006) Ann Intern Med , vol.144 , pp. 865-76
    • Kremer, J.M.1    Genant, H.K.2    Moreland, L.W.3    Russell, A.S.4    Emery, P.5    Abud-Mendoza, C.6
  • 29
    • 42449098374 scopus 로고    scopus 로고
    • Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
    • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008 58 : 953 63.
    • (2008) Arthritis Rheum , vol.58 , pp. 953-63
    • Kremer, J.M.1    Genant, H.K.2    Moreland, L.W.3    Russell, A.S.4    Emery, P.5    Abud-Mendoza, C.6
  • 30
    • 47949111861 scopus 로고    scopus 로고
    • Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial
    • Genant HK, Peterfy CG, Westhovens R, Becker J, Aranda R, Vratsanos G et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. Ann Rheum Dis 2008 67 : 1084 9.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1084-9
    • Genant, H.K.1    Peterfy, C.G.2    Westhovens, R.3    Becker, J.4    Aranda, R.5    Vratsanos, G.6
  • 31
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 353 : 1114 23.
    • (2005) N Engl J Med , vol.353 , pp. 1114-23
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3    Luggen, M.4    Sherrer, Y.5    Kremer, J.6
  • 32
    • 41849120516 scopus 로고    scopus 로고
    • Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    • Genovese MC, Schiff M, Luggen M, Becker J, Aranda R, Teng J et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008 67 : 547 54.
    • (2008) Ann Rheum Dis , vol.67 , pp. 547-54
    • Genovese, M.C.1    Schiff, M.2    Luggen, M.3    Becker, J.4    Aranda, R.5    Teng, J.6
  • 33
    • 33749586734 scopus 로고    scopus 로고
    • Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial
    • (Oxford)
    • Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006 45 : 1238 46.
    • (2006) Rheumatology , vol.45 , pp. 1238-46
    • Westhovens, R.1    Cole, J.C.2    Li, T.3    Martin, M.4    MacLean, R.5    Lin, P.6
  • 34
    • 47949106400 scopus 로고    scopus 로고
    • Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008 67 : 1096 103.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1096-103
    • Schiff, M.1    Keiserman, M.2    Codding, C.3    Songcharoen, S.4    Berman, A.5    Nayiager, S.6
  • 35
    • 33749365296 scopus 로고    scopus 로고
    • Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
    • Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006 54 : 2807 16.
    • (2006) Arthritis Rheum , vol.54 , pp. 2807-16
    • Weinblatt, M.1    Combe, B.2    Covucci, A.3    Aranda, R.4    Becker, J.C.5    Keystone, E.6
  • 36
    • 33846853779 scopus 로고    scopus 로고
    • Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial
    • Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis 2007 66 : 228 34.
    • (2007) Ann Rheum Dis , vol.66 , pp. 228-34
    • Weinblatt, M.1    Schiff, M.2    Goldman, A.3    Kremer, J.4    Luggen, M.5    Li, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.